
    
      The investigator's purpose is to study the population pharmacokinetics of paracatamol and
      ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of
      dosage individualization. In this study, the investigator will detect drug concentration in
      plasma and other clinical test to construct population pharmacokinetic models.
    
  